Q linea AB
F:3F8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Q linea AB
F:3F8
|
SE |
|
P
|
PPC Ltd
JSE:PPC
|
ZA |
|
Spinnova Oyj
F:9HP
|
FI |
|
S
|
Samsung C&T Corp
KRX:02826K
|
KR |
|
W
|
Wipro Ltd
BSE:507685
|
IN |
|
W
|
Warrix Sport PCL
SET:WARRIX
|
TH |
|
C
|
Capita PLC
DUS:CTAA
|
UK |
|
H
|
Hackett Group Inc
DUS:AWT
|
US |
|
Liberty Latin America Ltd
NASDAQ:LILA
|
US |
|
D
|
Dongfang Electric Corp Ltd
XBER:DEU
|
CN |
|
Mobimo Holding AG
F:M1H
|
CH |
|
A
|
Ameresco Inc
SWB:4AM
|
US |
|
Dexcom Inc
XETRA:DC4
|
US |
|
Ammo Inc
F:92P
|
US |
|
Fu Shou Yuan International Group Ltd
HKEX:1448
|
CN |
Q linea AB
Q-linea AB is a Swedish medical technology company that makes diagnostic instruments for hospitals and clinical laboratories. Its main product is ASTar, a system that helps identify how quickly a patient’s bacterial infection responds to different antibiotics. The company also sells the consumables and software that go with the instrument, so labs can run the test as part of routine work. Its customers are mainly hospital laboratories, reference labs, and other healthcare groups that need faster answers for serious infections. Q-linea makes money by selling or placing its instruments and by recurring sales of test cartridges and related supplies used each time a sample is analyzed. That mix gives the business both equipment sales and repeat revenue from ongoing testing. What makes Q-linea different is its role in the infection-diagnostics chain: it does not make broad lab equipment, but a focused tool for antibiotic susceptibility testing. That matters because doctors need fast, reliable information to choose the right antibiotic sooner, and labs need systems that fit into their existing workflow. Q-linea’s business is tied to the demand for better infection testing rather than to general healthcare software or consumer medical products.
Q-linea AB is a Swedish medical technology company that makes diagnostic instruments for hospitals and clinical laboratories. Its main product is ASTar, a system that helps identify how quickly a patient’s bacterial infection responds to different antibiotics. The company also sells the consumables and software that go with the instrument, so labs can run the test as part of routine work.
Its customers are mainly hospital laboratories, reference labs, and other healthcare groups that need faster answers for serious infections. Q-linea makes money by selling or placing its instruments and by recurring sales of test cartridges and related supplies used each time a sample is analyzed. That mix gives the business both equipment sales and repeat revenue from ongoing testing.
What makes Q-linea different is its role in the infection-diagnostics chain: it does not make broad lab equipment, but a focused tool for antibiotic susceptibility testing. That matters because doctors need fast, reliable information to choose the right antibiotic sooner, and labs need systems that fit into their existing workflow. Q-linea’s business is tied to the demand for better infection testing rather than to general healthcare software or consumer medical products.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
